Antigen News and Research

RSS

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

At the close of this year’s G7 Leaders’ summit, the Prime Minister of the United Kingdom of Great Britain and Northern Ireland announced a donation of an additional 870 million vaccine doses from attendees, with the majority to be delivered through COVAX, the vaccines pillar of the Access to COVID 19 Tools Accelerator, within the next year.

15 Jun 2021

SARS-CoV-2 oral vaccine booster shows promise in animal tests

In a recent study published on the pre-print bioRxiv* server, a group of Israeli researchers discusses their progress towards developing an oral multi-antigen SARS-CoV-2 vaccine.

15 Jun 2021

UMSOM researchers develop two accurate, rapid diagnostic tests for COVID-19

Researchers at the University of Maryland School of Medicine have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories.

15 Jun 2021

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

A new bioRxiv* preprint demonstrates how a combination of antibodies to two different regions on the viral spike could enhance neutralization efficiency as well as prevent the emergence of resistant variants.

15 Jun 2021

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

A reassuring study, released as a preprint on the medRxiv* server, from a multi-institutional team of researchers in Italy suggests that with the Pfizer-BioNTech BNT162b2 vaccine, post-vaccination immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is both robust and durable.

14 Jun 2021

Can rapid antigen tests help screen for COVID-19?

The spread of SARS-CoV-2 is driven by the high proportion of asymptomatic and very mild infections, allowing people to move around and engage in public activity normally. There are many modeling studies that suggest that large-scale screening for the presence of this virus can help curb transmission at this point, from people with few or no symptoms. A new study points out the accuracy of SARS-CoV-2 antigen-detection rapid diagnostic tests for this purpose when used at the point-of-care.

14 Jun 2021

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

The Native Antigen Company, part of LGC Clinical Diagnostics, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards.

From The Native Antigen Company 14 Jun 2021

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

A new commentary, published as an ‘In-Press Preview’ in the Journal of Clinical Investigation, addresses the salient issue of vaccination against the coronavirus disease (COVID-19) in pregnancy and potential antibody transfer to the fetus – and provides the evidence in support of messenger RNA (mRNA) vaccine safety and efficacy for both maternal and child health.

13 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

Researchers in the United States have developed a new coronavirus disease 2019 (COVID-19) vaccine that induced potent neutralizing antibodies against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal models.

10 Jun 2021

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

Trained dogs can accurately identify COVID-19 by scent

An interesting new medRxiv* preprint reveals that with careful training, the exquisite scent sensitivity of dogs may be exploited to rule out the presence of coronavirus disease 2019 (COVID-19) in human beings in real-time.

9 Jun 2021

The potential of mRNA vaccines for a wide range of diseases

A new review article published in the journal Briefings in Functional Genomics focuses on the general characteristic features and mechanisms of mRNA vaccines. Further, this review has summarized the current progress of mRNA vaccines that have been developed for wide-ranging diseases, including COVID-19 disease.

8 Jun 2021

Antihistamines might be effective in long-COVID

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.

8 Jun 2021

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

A new medrxiv* preprint reports on the current landscape of vaccine-induced antibodies in the United Kingdom.

8 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Immunomodulatory therapies for nephrological autoimmune diseases may help treat severe COVID-19

Various viruses and bacteria have long been known to cause autoimmune diseases where there is such a predisposition. This phenomenon also seems to play a major role in SARS-CoV-2, especially in severe courses.

8 Jun 2021

Restoring gut microbes can improve antibiotic-induced dysbiosis and prevent colitis in mice

A new study at the University of Chicago has determined that restoring a single microbial species -- Bacteroides sp. CL1-UC (Bc) -- to the gut microbiome at a key developmental timepoint can prevent antibiotic-induced colitis in a mouse model of the condition.

7 Jun 2021

Antigen News and Research

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

SARS-CoV-2 oral vaccine booster shows promise in animal tests

UMSOM researchers develop two accurate, rapid diagnostic tests for COVID-19

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

Can rapid antigen tests help screen for COVID-19?

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

Trained dogs can accurately identify COVID-19 by scent

The potential of mRNA vaccines for a wide range of diseases

Antihistamines might be effective in long-COVID

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

Immunomodulatory therapies for nephrological autoimmune diseases may help treat severe COVID-19

Restoring gut microbes can improve antibiotic-induced dysbiosis and prevent colitis in mice

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics